Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
- 22 February 2021
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5), 980-991
- https://doi.org/10.1111/pai.13484
Abstract
Background Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date. Methods ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period. Results Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution. Conclusion In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.Keywords
Funding Information
- Novartis
This publication has 29 references indexed in Scilit:
- Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma - eine AnwendungsbeobachtungPneumologie, 2013
- Add-on omalizumab in children with severe allergic asthma: a 1-year real life surveyEuropean Respiratory Journal, 2013
- The oral corticosteroid-sparing effect of omalizumab in children with severe asthmaArchives of Disease in Childhood, 2012
- Omalizumab and the risk of malignancy: Results from a pooled analysisJournal of Allergy and Clinical Immunology, 2012
- The minimally important difference of the Asthma Control TestJournal of Allergy and Clinical Immunology, 2009
- Development and validation of a questionnaire to assess asthma control in pediatricsPediatric Pulmonology, 2008
- Development and cross-sectional validation of the Childhood Asthma Control TestJournal of Allergy and Clinical Immunology, 2007
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006
- Development of the asthma control test: A survey for assessing asthma controlJournal of Allergy and Clinical Immunology, 2004
- Development and validation of a questionnaire to measure asthma controlEuropean Respiratory Journal, 1999